N4 Pharma PLC
0GO
Company Profile
Business description
N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec and its liptide platform called ECP105.
Contact
C/o Arch Law Limited
8 Bishopsgate
Huckletree Bishopsgate
LondonEC2N 4BQ
GBRSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,815.30 | 5.00 | -0.06% |
| CAC 40 | 7,793.94 | 35.35 | -0.45% |
| DAX 40 | 24,018.80 | 236.51 | -0.98% |
| Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
| FTSE 100 | 8,975.78 | 34.66 | 0.39% |
| HKSE | 24,203.32 | 63.75 | 0.26% |
| NASDAQ | 20,585.53 | 45.14 | -0.22% |
| Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
| NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
| S&P 500 | 6,259.75 | 20.71 | -0.33% |
| S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
| SSE Composite Index | 3,519.65 | 9.47 | 0.27% |